Table 1. Patients characteristics.

Patient no.	Sex Age	Primary diagnosis	TNM at diagnosis and histology	Comorbidity	PS 1	Localization in esophagus (from incisor teeth)	Previous oncological/surgical treatment
1	Male 77 yr	Jun 2016	T3N1M0 SCC	COPD	2	32 – 40 cm	Stent RT: 3 Gy × 10 F (esophagus)
2	Male 59 yr	May 2015	T4bN0M0 ADC	Liver insufficiency (Child Pugh A), esophageal varices	1	20 – 34 cm	Capecitabine/oxaliplatin/trastuzumab RCT: 2 Gy × 25 F + Cisplatin/5 – fluorouracil Docetaxel
3	Male 60 yr	Apr 2015	T3N2M1 ADC	DMII (Liver and osteolytic metastases)	2	34 – 41 cm (“metastatic islands” starting from 20 cm)	Capecitabine/ trastuzumab RT: 3 Gy × 10 F (esophagus) RT: 5 Gy × 5 F (costae)
4	Male 84 yr	Feb 2016	T2 /3N0M0 ADC	Hypertension, AF, epilepsy Previous: prostate cancer	2	34 – 42 cm	RT: 3 Gy × 10 F (esophagus)
5	Male 80 yr	Apr 2014	T1N1M0 ADC	Hypertension, AF, hypercholesterolemia, essential thrombocytosis Previous: ischemic stroke	2	34 – 42 cm	RT: 3 Gy × 10 F (esophagus)
6	Female 72 yr	Nov 2015	TxNxM1 ADC	Hypertension, DMII (Peritoneal carcinonomatosis)	1	38 – 40 cm	3 Gy × 10 F (esophagus) Argon plasma coagulation Capecitabine/oxaliplatin/trastuzumab Irinotecan
7	Male 88 yr	Feb 2017	T3N0M0 ADC	Parkinson’s disease, AA, possible prostate cancer	2	30 – 40 cm	None

COPD, chronic obstructive pulmonary disease; RT, radiotherapy; Gy, Gray; F, fraction; RCT, radiochemotherapy; SCC, squamous cell carcinoma; ADC, adenocarcinoma; DMII, diabetes mellitus type II; AF, atrial fibrillation; AA, aortic aneurysm

¹Performance status according to WHO/ECOG [18]